GeneHealth - Your precision medicine

Citrullinemia

Disease Details

Family Health Simplified

Buy Membership

Description: Citrullinemia is a rare genetic disorder characterized by an inability to properly convert ammonia into urea, leading to toxic levels of ammonia in the blood.
Type: Citrullinemia is a type of urea cycle disorder. It follows an autosomal recessive pattern of genetic transmission.
Signs And Symptoms: Signs and symptoms of citrullinemia can vary. Common signs and symptoms include:

1. Ammonia buildup in the blood
2. Vomiting
3. Lethargy
4. Seizures
5. Poor feeding
6. Coma
7. Developmental delays
8. Liver abnormalities

In severe cases, especially in newborns, citrullinemia can be life-threatening if not treated promptly.
Prognosis: Citrullinemia is a rare genetic disorder that leads to the accumulation of ammonia and other toxic substances in the blood. The prognosis for citrullinemia can vary significantly based on the type and timing of diagnosis and treatment:

1. **Type 1 Citrullinemia:**
- Neonatal-Onset: If untreated, the prognosis is poor due to severe hyperammonemia leading to neurological damage, coma, or death. Early diagnosis and aggressive treatment can improve outcomes, with some individuals achieving near-normal cognitive and physical development.
- Late-Onset: The prognosis is generally better than in the neonatal form but can still be variable. With proper management, many individuals lead relatively normal lives, though they may experience episodes of hyperammonemia.

2. **Type 2 Citrullinemia:**
- Generally, the prognosis is better than for Type 1. Symptoms typically appear in adulthood and can often be managed with dietary changes and medication. With appropriate treatment, individuals can lead healthy lives, but ongoing medical supervision is usually necessary.

The key to a more favorable prognosis in both types is early detection and consistent management of the condition.
Onset: Citrullinemia is a genetic disorder that can present in two major forms:

1. **Type I Citrullinemia** typically has an onset in the neonatal period shortly after birth. Infants may exhibit symptoms such as poor feeding, vomiting, lethargy, and seizures. If left untreated, it can lead to severe neurological impairment or death.

2. **Type II Citrullinemia** often presents later in life, usually in adulthood, although symptoms can occasionally appear in adolescence. Symptoms may include confusion, abnormal behavior, and psychiatric symptoms, and can eventually lead to coma and death if untreated.

The term "nan" is not applicable in the context of citrullinemia. If referring to a specific aspect of the disease, please clarify further.
Prevalence: Citrullinemia is a rare genetic disorder with an estimated prevalence of about 1 in 57,000 to 1 in 250,000 live births worldwide. This range indicates variability depending on the population being studied.
Epidemiology: **Citrullinemia:**

**Epidemiology**
Citrullinemia is a rare genetic disorder, classified under urea cycle disorders. The prevalence is estimated to be roughly 1 in 57,000 to 1 in 250,000 live births worldwide. The disorder is more common in certain geographic regions and ethnic groups, such as the Amish community in the United States, where the prevalence is higher due to a founder effect.

Please specify if you meant something different by "nan" or if there is additional specific information you require.
Intractability: Citrullinemia is a genetic disorder that can be challenging to manage but is not necessarily intractable. There are two main types:

1. **Citrullinemia Type I (CTLN1)**: With early diagnosis and proper treatment, which often includes dietary management and medications to remove excess ammonia, patients can manage the symptoms effectively.
2. **Citrullinemia Type II (CTLN2)**: This type typically presents in adulthood and may be managed with a low-protein diet and medications, though severe cases may still pose significant challenges.

Overall, while citrullinemia requires ongoing management and can have serious complications, it is not considered intractable with appropriate medical care.
Disease Severity: Citrullinemia can vary in severity based on its type. There are primarily two types:

1. Type I Citrullinemia (CTLN1):
- Disease Severity: This form is usually more severe and presents in newborns or infants. It can cause serious symptoms including vomiting, lethargy, seizures, and coma due to hyperammonemia (high levels of ammonia in the blood).

2. Type II Citrullinemia (CTLN2):
- Disease Severity: This form typically appears in adulthood and can range in severity. Symptoms can include confusion, lethargy, seizures, and in severe cases, coma. Some patients may experience milder symptoms or remain asymptomatic for long periods.

Both types are considered serious and potentially life-threatening without appropriate management.
Healthcare Professionals: Disease Ontology ID - DOID:9273
Pathophysiology: Citrullinemia is a rare genetic disorder characterized by a deficiency of the enzyme argininosuccinate synthetase (ASS) or argininosuccinate lyase (ASL), depending on the type. This deficiency impairs the urea cycle, which is responsible for removing ammonia from the bloodstream. As a result, toxic levels of ammonia accumulate in the blood (hyperammonemia), leading to neurological damage and other severe symptoms.
Carrier Status: Citrullinemia is an inherited disorder primarily affecting the urea cycle, leading to an accumulation of ammonia in the blood. There are two main types: Type I and Type II.

In regard to carrier status:
- This condition is inherited in an autosomal recessive manner. This means that a person needs to inherit two defective copies of the gene (one from each parent) to be affected by the disorder.
- Carriers, who have only one defective copy of the gene, typically do not display symptoms but can pass the gene to their offspring.

Regarding the term "nan", it is not clear in this context. If it refers to "not a number" or if it’s a typographical error, it doesn't have a direct correlation with citrullinemia or its carrier status. If you meant something else, please clarify.
Mechanism: Citrullinemia is a rare genetic disorder that affects the urea cycle, which is the body's process of removing ammonia from the bloodstream. The disease is characterized by an accumulation of ammonia and other toxic substances in the blood due to a deficiency in the enzyme argininosuccinate synthetase (ASS1).

### Mechanism:
1. **Urea Cycle Dysfunction:** Citrullinemia disrupts the urea cycle, specifically at the step where citrulline is converted to argininosuccinate. This step requires the enzyme argininosuccinate synthetase.
2. **Ammonia Accumulation:** Due to the enzyme deficiency, citrulline and ammonia accumulate in the blood. Ammonia is particularly toxic to the brain and can lead to severe neurological complications if not managed.

### Molecular Mechanisms:
1. **Genetic Mutation:** Citrullinemia is primarily caused by mutations in the ASS1 gene, which provides instructions for producing argininosuccinate synthetase. Mutations in this gene lead to reduced or absent enzyme activity.
2. **Enzymatic Deficiency:** The lack of functional argininosuccinate synthetase prevents the normal conversion of citrulline and aspartate into argininosuccinate, an essential step in the urea cycle.
3. **Metabolic Consequences:** The disruption of this pathway leads to the build-up of citrulline and ammonia in the blood. Elevated levels of ammonia (hyperammonemia) are especially harmful as they can cross the blood-brain barrier and cause cerebral edema and other neurological symptoms.

Overall, citrullinemia results from enzymatic dysfunction caused by genetic mutations, leading to urea cycle disruption and toxic ammonia accumulation.
Treatment: There are multiple treatment methods. Low protein diets are intended to minimize production of ammonia. Arginine, sodium benzoate and sodium phenylacetate help to remove ammonia from the blood. Dialysis may be used to remove ammonia from the blood when it reaches critical levels.
In some cases, liver transplant has been successful.
Compassionate Use Treatment: Citrullinemia is a rare genetic disorder characterized by the accumulation of ammonia and other toxic substances in the blood due to defective function of the urea cycle. For compassionate use and off-label treatments, options are often considered when conventional therapies fail or are insufficient.

1. **Liver transplant**: This can be a definitive treatment option for some patients with severe urea cycle disorders, including citrullinemia. While not a standard initial therapy, it may be considered in cases of persistent metabolic decompensation.

2. **Sodium Phenylbutyrate**: Although typically used for treating urea cycle disorders, it might be used off-label to help manage hyperammonemia in citrullinemia.

3. **Sodium Benzoate**: Occasionally used off-label to help reduce ammonia levels in conjunction with other treatments.

4. **Gene therapy and enzyme replacement therapy (ERT)**: Both are experimental treatments currently under investigation for urea cycle disorders, including citrullinemia.

It is essential for these treatments to be managed and supervised by specialists experienced with metabolic disorders.
Lifestyle Recommendations: For citrullinemia, lifestyle recommendations often focus on dietary management and regular medical monitoring. Here are some key recommendations:

1. **Dietary Restrictions:**
- **Low-Protein Diet:** Limit intake of high-protein foods to reduce the amount of ammonia produced during protein metabolism.
- **Special Formulas:** Use specially formulated medical foods or formulas that provide necessary nutrients without adding excessive protein.
- **Frequent Meals:** Eat smaller, more frequent meals to prevent spikes in ammonia levels.

2. **Medication Adherence:** Take prescribed medications consistently to help manage ammonia levels and other symptoms.

3. **Regular Monitoring:**
- **Blood Tests:** Regular blood tests to monitor ammonia and amino acid levels.
- **Neurological Assessments:** Regular check-ups to monitor for any neurological changes or developmental delays.

4. **Hydration:** Maintain proper hydration to help kidneys excrete waste products.

5. **Emergency Plan:** Have an emergency plan in place, including knowledge of symptoms of hyperammonemia and quick access to medical care.

6. **Avoiding Stressors:** Minimize factors that can increase protein breakdown, such as infections, surgery, or physical stress.

Lifestyle adjustments should always be made under the guidance of healthcare professionals specialized in metabolic disorders.
Medication: Citrullinemia is a rare genetic disorder that affects the urea cycle, leading to an accumulation of ammonia in the blood. Treatment primarily focuses on managing ammonia levels.

Medications may include:
1. **Sodium phenylbutyrate** - Helps to excrete excess nitrogen.
2. **Arginine supplementation** - Enhances the urea cycle function.
3. **Ammonul (sodium phenylacetate and sodium benzoate)** - Used for acute hyperammonemia episodes.

Dietary management, liver transplantation, and gene therapy are other potential treatment options. Regular monitoring and specialized care are crucial.
Repurposable Drugs: For citrullinemia, there are no well-established repurposable drugs available. Treatment typically centers around managing symptoms and reducing ammonia levels through dietary restrictions, supplements like arginine, and ammonia-scavenging drugs such as sodium phenylbutyrate. Severe cases may require liver transplantation.
Metabolites: Citrullinemia is characterized by elevated levels of citrulline in the blood. It's a urea cycle disorder caused by deficiencies in the enzymes that process nitrogen. Consequently, this leads to the accumulation of ammonia, which can be toxic. The main metabolic hallmark is high plasma citrulline levels.
Nutraceuticals: For citrullinemia, there are no specific nutraceuticals that are widely recognized or approved as a primary treatment. Citrullinemia is a genetic disorder involving the urea cycle, and treatment typically focuses on dietary management and medications to reduce ammonia levels. Nutraceuticals might be used to support overall health, but they are not a substitute for medical treatment. Always consult a healthcare provider for managing this condition.
Peptides: Citrullinemia is a metabolic disorder characterized by an excess accumulation of citrulline in the blood due to a deficiency of the enzyme argininosuccinate synthetase (ASS1). Peptides relevant to citrullinemia include those involved in the urea cycle, such as citrulline itself and its metabolites. The term "nan" appears ambiguous in this context; if it refers to the nanomolar (nM) concentration ranges of peptides and metabolites in clinical testing, these measures can be crucial for diagnosing and understanding the severity of the disorder. Alternatively, "nan" might signify "not a number" or absence of data. In such cases, providing a clearer context would enhance the response accuracy.